Thus, the decreased OPN content in the urine by CBG treatment may limit glomerular damage and protect against the development of inflammation in kidney damage and its progression to pro-fibrotic stages, suggesting that CBG might serve as a therapeutic agent [63]. This evidence concerns the gene SPP1 and Nephropathy.